# Efficacy and Safety of Pemafibrate for Nonalcoholic Fatty Liver Disease

> **NCT06623539** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Yokohama City University** · enrollment: 360 (actual)

## Conditions studied

- Non Alcoholic Fatty Liver Disease

## Interventions

- **DRUG:** Pemafibrate high dose
- **DRUG:** Pemafibrate low dose
- **DRUG:** Fenofibrate

## Key facts

- **NCT ID:** NCT06623539
- **Lead sponsor:** Yokohama City University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-12-23
- **Primary completion:** 2025-06
- **Final completion:** 2026-03
- **Target enrollment:** 360 (ACTUAL)
- **Last updated:** 2024-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06623539

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06623539, "Efficacy and Safety of Pemafibrate for Nonalcoholic Fatty Liver Disease". Retrieved via MORVS 2026-09-29 from https://api.morvs.ai/clinical/NCT06623539. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*